AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback